Terms of the deal have not been disclosed, but Oracle said that it will add Relsys to its Health Sciences global business unit.
The database vendor claimed in a report that the combination of expertise will deliver the "only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care".
"The health sciences industry is increasing investments in software that provides greater transparency into drug safety, and helps improve the overall safety of therapies," said Neil de Crescenzo, Oracle Health Sciences senior vice president and general manager.
"With the addition of Relsys, Oracle is uniquely positioned to help our customers improve drug safety by delivering a comprehensive software solution that enables our vision of integrated safety and risk management supported by advanced analytics."
Commons Science and Technology Committee calls for new post-Brexit skilled-workers immigration system
Committee calls for visa-free travel and permit-free work for skilled workers
Eleven 'normal' outer moons, and one described as 'oddball' found circling Jupiter
Scientific discovery has found a quadrillion tonnes of diamonds in the earth's mantle
Mobile payment app makes users' details public by default